Greenfire Bio

Greenfire Bio operates as a life science development and investment company, led by a team of experienced biopharma executives, building a diversified product pipeline by developing early-stage assets through proof of concept and investing in unique medical breakthroughs. Greenfire typically licenses, acquires, partners, or invests in differentiated pre-clinical or early clinical-stage programs to bridge the translational medicine gap and accelerate development.

Ajit Gill

CEO and President

1 past transactions

Pacylex

Series A in 2021
Pacylex Pharmaceuticals is focused on developing precision medicine solutions for various common cancers, including both blood and solid tumors. The company is advancing PCLX-001, a small molecule oral chemotherapeutic designed to induce selective lethality in cancer cells by targeting membrane-associated proteins involved in cancer signaling. This innovative approach aims to provide a potent alternative to traditional chemotherapies and immunotherapies. Additionally, Pacylex has created diagnostic technology to identify patients who are most likely to benefit from PCLX-001, thereby avoiding unnecessary treatments for those who would not respond. Founded in 2012 and based in Edmonton, Alberta, Canada, Pacylex Pharmaceuticals is pioneering first-in-kind therapies that may transform cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.